Intravitreal injections and diabetic macular edema: actual and new therapeutic options.

Abstract

The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/ grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual outcome in patients with diabetic retinopathy. Hence, anti-VEGF injections are considered the new gold standard to treat diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens are underway to define better clinical care pathways.

• Authors: Nicola Pescosolido, Federica Pranno, Giuseppe Buomprisco
• Journal: Current diabetes reviews (Curr Diabetes Rev) Vol. 9 Issue 6 Pg. 491-8 (Nov 2013) ISSN: 1875-6417 [Electronic] United Arab Emirates
• PMID: 24160355 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A

Topics

• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Combined Modality Therapy
• Diabetic Retinopathy (pathology, therapy)
• Female
• Humans
• Intravitreal Injections
• Laser Coagulation (methods)
• Macular Edema (pathology, therapy)
• Male
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity